Gastroenterology: Benzabert can effectively treat itching symptoms in fibrosis bile tube disease.

Itching of the skin of patients with primary or secondary sclerotic bile rhinitis (PSC, SSC) and primary bile silting disorders such as pBC may seriously impair their quality of life.
benzodiabet is a widely used peroxidase proliferative polymerizer (PPAR) astigtor that reduces bile silt-related itching by reducing liver and bile damage.
the study, which was initiated by researchers, was designed to assess the therapeutic effect of benzodiabet on itching symptoms in patients with PSC, PBC and SSC.
method researchers included patients with PSC, PBC, or SSC with moderate to severe itching (5 points for vision simulation (VAS)) and randomly gave the patient a placebo or benzodiabet (400mg/d) treatment for 21 days.
observational endpoint was a 50% reduction in itching scores.
results showed that 70 out of 74 randomized patients completed the trial (44 PSC, 24 PBC, 2 SSC).
benzodiabet can reduce severe or moderate itching by 45% (41% PSC, 55% PBC) and placebo by only about 11% (p s 0.003).
For secondary endpoints, benzodiabet mainly reduced itching intensity in the morning (p s 0.01) and evening (p s 0.007), and benzozabert also reduced serum alkaline phosphatase levels (-35%, p s 0.03), suggesting that the patient's bile damage was reduced.
serum bile acid and self-secretion exercise activity remained unchanged.
benzodiabet is a good drug for improving moderate to severe itching in PSC and PBC patients.
.